Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants with Moderate to Severe Hidradenitis Suppurativa

Who can participate?    

• Must be at least 18 years old
• Have had a diagnosis of Hidradenitis Suppurativa for at least 6 months

How long is the study?    

• A screening period of up to 5 weeks
• A 48-week study drug period
• A safety follow up visit

What does it entail?    

• 16 weeks of either the study drug ( bimekizumab) or placebo
• 32 weeks of the study drug
• Two injections of bimekizumab or placebo every two weeks from Week 0 to Week 46